Contact REGHELPS SRC
Talk to our clinical and regulatory team about PMCF studies, clinical investigations, usability studies, IVD performance studies, CE marking, FDA submissions or your quality system. Tell us about your device and we will suggest the right next step.
How would you like to get in touch?
From your enquiry to project kick-off
A simple, transparent process with no obligation until you approve a proposal.
Send us a message
REGHELPS offices in India and the USA
Bengaluru, India
RegHelps SRC Private Limited#303, Shakthi Mansion, 2nd Block
Ramamurthy Nagar, Bengaluru 560016
Karnataka, India
Bengaluru, India
#1383, 5th Block, HBR LayoutOuter Ring Road, Bengaluru 560043
Karnataka, India
Delhi, India
51A, Pratap Nagar, Gali No 2Mayur Vihar, Delhi 110091
India
North Carolina, USA
Regseek LLCEmeline Way, Fuquay-Varina
NC 27526, USA
Contact FAQs
How quickly will REGHELPS reply to my enquiry?
We aim to reply to every enquiry within one business day. For urgent regulatory deadlines, mention the date in your message or call us directly.
Can we sign an NDA before sharing device details?
Yes. We are happy to sign a confidentiality agreement before you share technical, clinical or commercial information about your device.
Which countries and markets do you support?
We support manufacturers worldwide from our offices in India and the USA, with services covering the EU MDR and IVDR, US FDA, UK MHRA and India CDSCO requirements.
What should I include in my message?
Your device or IVD, its intended purpose and risk class if known, your target markets, the service you need and any deadlines. This helps us send an accurate proposal faster.
Do you offer a free initial consultation?
Yes. Your first discussion with our team is free, and we can usually suggest the right approach, such as a study design or regulatory route, before you commit.
Can I request a quote for a single service?
Yes. You can request a quote for one service, such as a PMCF study or a technical file review, or for a complete programme from clinical evidence to market approval.

